The European Union is facing a shortage of medicines, including antibiotics and children's drugs, due to high demand and low production.

Spain's drug shortage has risen 38% in the past year due to inflation and high energy prices.

The EU Pharmaceutical Group and European Commission are taking steps to address the pharmaceutical shortage.

The US saw a record 323 drug shortages in 2024, particularly affecting sterile injectable generics.

The average shortage affects over 500,000 patients and typically lasts more than two years.

Manufacturing and quality problems are the primary causes of most drug shortages.

Lack of transparency in the pharmaceutical industry hinders healthcare systems' response to shortages.

The FDA monitors the supply chain, but more needs to be done to prevent shortages.

Production problems and quality issues are common causes of drug shortages.

The US faced 323 drug shortages in Q1 2024, including chemotherapy and ADHD medications.

The White House has proposed $3.26-5.11 billion to address drug shortages, and US researchers suggest changing the pharmaceutical industry business model.

The FDA needs more power to access drug shortage information and manufacturers need to be more transparent.

Medication shortages have a significant economic impact on healthcare systems, resulting in substantial costs and burdens.

Medication shortages can increase prices by 16.6 percent and alternative treatments can cost at least three times more.

Technology like AI and data analytics can help predict and address medication shortages, but its benefits and limitations need further exploration.

KPIs for medication shortage mitigation strategies include waiting time reduction and improved patient access.

Implementing a "Universal Health Insurance Cost Distribution Target System" and a "Drug Supply Information Platform" can help track and manage drug shortages.

Constructing centralized production bases and promoting review and approval of shortage drugs can help address drug shortages.

The National Health Commission and State Medical Insurance Bureau monitor and track drug shortages and prices.

Waiting time reduction and improved patient access can be used as KPIs to measure mitigation strategy effectiveness.

Patient registration and drug collection times can be used as a KPI to measure mitigation strategy effectiveness.

Medication shortages require a multifaceted approach, including improved manufacturing, quality control, and industry transparency.

Technology and KPIs can help predict, address, and evaluate medication shortages and mitigation strategies.

The EU has proposed a voluntary solidarity mechanism to address medication shortages, including an early warning system and joint drug procurement.

The EU will set up an early warning system for scarce drugs and implement emergency measures.

The Ministry of Health has allocated 240 billion rubles for drug provision and introduced a labeling system for real-time tracking.

The registration process for medicinal products will be simplified.

The National shortage drug classification system has been improved and urgent drugs temporarily imported.

A mechanism for stable drug prices is being discussed and drug information monitoring has improved.

The Ministry of Health plans to establish a "shortage of drugs center" and set a "floor price" for drugs.

The EU has created a strategic supply of scarce drugs and obliges manufacturers to guarantee supply.

A law will be introduced to ensure patient access to medicines, with stricter supplier obligations and earlier shortage notifications.

The European Commission proposes shortening drug evaluations from 210 to 180 days, but NGOs oppose it, citing insufficient time for safety checks.

The EU may require pharmaceutical companies to hold safety stocks and has shortened data protection for generic medicines to 7.5 years.

The Ministry of Health has proposed a strategy to address drug shortages, including coping mechanisms and a drug price adjustment.

The FDA requires manufacturers to report supply interruptions and production disruptions.

The US Senate reported that nearly 300 pharmaceutical products were affected by shortages in the US in 2022.

China has strengthened anti-unfair competition law enforcement in the pharmaceutical industry and issued a plan for medicine development.

The plan aims to promote innovative products, adjust medical insurance, and reform drug pricing.

The US faced 323 drug shortages in Q1 2024, including chemotherapy and ADHD medications.

The White House has proposed $3.26-5.11 billion to address drug shortages, and US researchers suggest changing the pharmaceutical industry business model.

The FDA needs more power to access drug shortage information and manufacturers need to be more transparent.

US shortages are mainly caused by a fragmented supply chain, particularly affecting non-patented sterile injectable drugs.

Chemotherapy and ADHD drugs are among those most affected by shortages.

The Hospital Authority purchased paracetamol from the Mainland due to a shortage, introducing non-local drugs.

The supply situation is stable, with original antibiotics restored, and the HA follows four purchasing principles, including registration.

Drugs must pass non-proprietary drug interchangeability tests and meet WHO bioequivalence requirements.

The HA prioritizes drugs with English labels and requires GMP regulation for purchased drugs.

Taiwan faces a shortage of 131 medicines, including amoxicillin and acetaminophen.

International pharmaceutical companies prioritize other countries over Taiwan due to its low prices, exacerbating medication shortages.

The US FDA has a "Drug Deficiency Monitoring Center" that can serve as a model for other countries.

The Ministry of Health and Welfare has failed to address drug shortages, a major concern for healthcare systems.

Medication shortages can cause severe health consequences, including permanent paralysis in multiple sclerosis patients, after the Ministry of Health withdrew support for 14 MS medicines.

The medication shortage affects multiple sclerosis and cancer patients, highlighting the need for organized distribution to treatment centers.

Riluzole, a medication for motor neurone disease, is in short supply, causing patient access difficulties and added distress.

The Department of Health is working with manufacturers and alternative suppliers to resolve shortages.

Cisatracurium, crucial for severe pneumonia, is in short supply, increasing the death rate, with no alternative for emergency intubation.

The Cisatracurium shortage significantly impacts patient outcomes and mortality.

Drug shortages can negatively impact pharmacy economies by 20% and harm patient health by limiting access to vital medicines.

The pharmaceutical sector is crucial for national security, and ongoing drug shortages threaten patients' lives.

Medication shortages can endanger patient lives by affecting vital systems and causing severe health issues.

The shortage of medication can last months, making initial shipments crucial for patient health despite potential alternative treatments.

Medication shortages affect various drugs, including Cisatracurium, for which alternatives are available for some.

A steady supply of Cisatracurium is needed to reduce intubation complications and mortality rates in severe pneumonia.

Medication shortages have severe consequences, including the deaths of 146 patients with thalassemia, cystic fibrosis, and hemophilia.

Iron accumulation in thalassemia patients causes serious complications, which are worsened by medication shortages.

In Lebanon, medicine shortages worsen due to the economic crisis, with cancer treatment drugs running out, potentially shortening patients' lives by 1-3 years.

The European Union is facing a shortage of medicines, including antibiotics and children's drugs, due to high demand and low production.

Title:

Content: There is not enough medicine in the EU
19 January 2023, 05: 20
ASTANA.
KAZINFORM - The European Union is suffering from a shortage of medicines.
Deficiency of antibiotics, such as amoxicillin, drugs against colds, flu and other respiratory infections, as well as some drugs for children, reports MIA "Kazinform" with reference to euronews.com.
In most countries, the situation is considered critical, but since such goods from pharmacies do not disappear at all, citizens are not advised to make stocks.
Doctors note a weakening in the population of natural immunity due to protection against coronavirus such as social distancing.
The main reasons for the sharp increase in demand, which have been identified, is the high prevalence of respiratory diseases with a lack of production capacity.
As pharmaceutical issues are being addressed at the national level, Governments are already taking steps to overcome the shortage
These measures include the sale of generics and the replacement of requested medicines with similar ones.
In some countries, some formulations have been changed, for example, drugs are offered in the form of syrups instead of tablets, so that children are more willing to take them.
"Pediatric drugs are generally now less available in the form of conventional tablets," said Steffen Tierstrup, chief medical officer of the European Medicines Agency. "Therefore, where children are more ill, the need for pediatric drugs is higher than for adult drugs."
A recent study showed that the shortage of drugs in Spain increased by 38% over the year.
The decline in their production was affected by inflation, high energy prices, shortages of raw materials and the effects of the pandemic.
“We need diversification, ” said Ilaria Passarani, head of the EU Pharmaceutical Group.“ Of course, it would be useful to return to Europe the production of some critical materials, such as active ingredients.
But we can't return all the production of all the materials we use for drugs.
This entails problems such as the increase in pharmacy prices associated with the implementation of environmental laws, labor laws, which are not necessarily enforced in other regions. ”
In March, the European Commission will present a revised version of the EU pharmaceutical legislation, which will include stricter supply obligations, earlier notification of shortages and seizures of medicines, and better informing the public about available stocks.
News on the topic
Partners news
News feed

Spain's drug shortage has risen 38% in the past year due to inflation and high energy prices.

The EU Pharmaceutical Group and European Commission are taking steps to address the pharmaceutical shortage.

The US saw a record 323 drug shortages in 2024, particularly affecting sterile injectable generics.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
An Unexpected Catastrophe in the World ’ s Largest Country: The Complete Story of U.S. Drug Shortages
The deficit is at a record level.
According to data from the American Society of Health System Pharmacists and the University of Utah Drug Information Service, organizations began tracking drug shortages for the first time in 2001. Steady since 2021 – now reaching a record high of 323 drugs in the first three months of 2024.
Paul Abramowitz, CEO of the American Society of Health System Pharmacists, wrote in a blog post on Thursday: “It ’ s been a long time to end drug shortages, ” and wrote:“ All drug classes are vulnerable to shortages, some of the most worrisome shortages include sterile injectable generic drugs, including cancer chemotherapy drugs and emergency drugs stored in hospital vans and procedural areas. It is dangerous for doctors and patients. ”
In addition to the 32 chemotherapy drugs that are deficient, the five categories of drugs with the greatest deficiency include central nervous system stimulants, antimicrobials, hormonal agents, and intravenous fluids. [1] The Drug Deficiency Database maintained by the American Society of Health System Pharmacists and the University of Utah is based on voluntary reports from practitioners, patients, and others that have been confirmed by manufacturers. The U.S. drug is in short supply, because it captures broader effects on service providers and patients.
The crisis has lasted a year and a half.
More than half of the treatment shortages have lasted for more than two years, according to an analysis by health consultancy IQVIA, and the average shortage affects at least half a million patients, many of them elderly, according to the US Office of Health and Human Services under the Assistant Secretary for Planning and Evaluation, which shared its analysis with Congress in May.
Growing demand can play a role in drug shortages, as with the recent shortage of weight-loss drugs, but often manufacturing and quality problems, such as supply chain gaps and downtime, are the root cause. And varied.
But the American Society of Health System Pharmacists has “serious concerns ” about parts of this proposal, especially financial sanctions imposed on hospitals that lack the resources to comply with the recommendations, Abramowitz wrote:“ We all know that managing shortages is not enough and is not a sustainable solution to the worsening crisis, and there is still a lot of work to be done at the federal level to fix the root causes of drug shortages. ”
Why Shortage Occurs
Shortages can be caused by high demand, as with the recent shortage of weight-loss drugs, but this is not usually the main problem.
The FDA also blames manufacturing and quality problems, supply chain gaps, and downtime, and Dr. Emily Tucker, a drug shortage expert and an assistant professor of industrial engineering at Clemson University, says that when there is an indication of shortages, large health systems often also proactively place large orders, adding to the system ’ s stress.
“I don ’ t blame anyone.
“When I talk to all the stakeholders – whether it ’ s wholesalers, manufacturers, or the government – everyone wants this problem to end, ” she said.
Lack of transparency
Dr. Julie Grallo, chief medical officer and executive vice president of the American Society of Clinical Oncology, told the House Committee earlier that the shortage puts providers in a terrible position: “The drug shortage crisis is forcing providers to make impossible choices, and it is also hindering the development of new drugs. Health drugs are purchased only on a price basis, and manufacturers do not have to disclose the source of their acquisition of the ingredients.
The shortage of this generic chemical drug came due to the closure of one factory in India that manufactures the active ingredient after a surprise FDA inspection found “significant quality issues, ” says Jarallo:“ We didn ’ t know, and there was no transparency regarding the company ’ s supply of the majority of active pharmaceutical ingredients to all manufacturers across the board.
Knowing this in advance, we could have responded much faster, ” Dr. Steven Schundlemeyer, director of the PRIME Institute of the University of Minnesota School of Pharmacy, which focuses on economic and management issues, told the committee that as with defense contractors in the United States, New Zealand requires manufacturers to disclose their suppliers, and that information is required.
Easily accessible in the database.
Related Topics

The average shortage affects over 500,000 patients and typically lasts more than two years.

Manufacturing and quality problems are the primary causes of most drug shortages.

Lack of transparency in the pharmaceutical industry hinders healthcare systems' response to shortages.

The FDA monitors the supply chain, but more needs to be done to prevent shortages.

Title:

Content: US supply chain crisis continues, FDA points to 111 drug shortages
Global Social Hotspot 16: 35 2021 / 12 / 05
Share:
The supply chain crisis in the United States continues, and many goods are facing shortages.
The US media said that the US pharmacies have a number of critical prescription drugs in stock. The US Food and Drug Administration (FDA) pointed out that about 111 drugs are out of stock in the United States. The FDA stressed that it will continue to take measures to monitor the supply chain.
【 Omicron variant 】 Travellers must have a negative test within 48 hours for entering the United Kingdom 【 Next 】
The Federal Reserve warned on Wednesday that large parts of the United States had begun to be affected by supply chain disruptions and labor shortages last month.
According to the FDA website, 111 drugs are out of stock in the United States, including the heart disease drug digoxin injection, the chemical drug Dacarbazine and some antibiotics.
The authorities say there are many reasons for the shortage, including production problems, quality problems, drugs and even the suspension of production.
According to the FDA, about 80% of the manufacturers of active pharmaceutical ingredients are located overseas, and the manufacturers have provided the FDA with most of the drug shortage information.
The Administration will also work closely with these manufacturers to address the drug shortage.
【 Omicron variant 】 Study: Omicron carries a cold virus gene or helps avoid the immune system 【 Next 】
Long Island Newspaper Newsday quoted Tom D'Angelo, president of the New York State Association of Pharmacists, as saying the shipping of a large number of medicines, including those for common blood pressure and for the treatment of colds and flu, was blocked.
Because of supply chain problems, the owner of a New York drugstore said there were fewer brands for some drugs, including Ibuprofen.
The National Association of Community Pharmacists (NCPA) released a survey last month that found that most non-chain pharmacies are struggling to fill employee vacancies and cope with supply chain disruptions.
Sixty percent of pharmacies surveyed said they were dealing with supply chain disruptions, and nearly 70 percent said it was difficult to fill staff vacancies.
Stay abreast of the latest development of mutant virus and epidemic vaccine, download the Hong Kong Economic Times App for free now 【 Click here
Editor-in-Chief: Cheng Kam-ling
Follow the latest financial news analysis, like hket Facebook
Subscribe to the Hong Kong Economic Times email newsletter
Receive first-hand financial news Learn more about investment and financial knowledge Submit my consent to receive promotional messages from Hong Kong Economic Times Group. You may also check the privacy policy of this website Terms of Use

Production problems and quality issues are common causes of drug shortages.

The US faced 323 drug shortages in Q1 2024, including chemotherapy and ADHD medications.

Title:

Content: Meitu
The first quarter of the United States serious drug shortage 323 drugs urgent cancer patients also have to be diverted and rationed!
CHU HENG NETWORK NEWS CENTER 2024-04-16 10: 42
According to the latest data from the American Society of Health System Pharmacists (ASHP) and the Utah Center for Drug Information Services, a total of 323 drugs in the United States were in severe shortages in the first quarter of this year, surpassing the record of 320 in 2014.
Among the drugs affected are the widely used diabetes drugs Ozempic and Mounjaro, the allergy treatment drug adrenaline, the common antibiotic amoxicillin for children, chemotherapy drugs and injections commonly used in hospitals in intensive care.
ASHP CEO Paul Abramowitz said in a statement that almost all categories of drugs are facing shortages, with non-patented sterile injectable drugs, including cancer chemotherapy drugs, and emergency drugs stored in hospital emergency vans and operating areas, the shortage of such drugs is the most worrying.
According to the American Cancer Society, chemotherapy is one of the top five drugs most affected by the shortage, which threatens to have a devastating impact on patients, and some hospitals and clinics say doctors have had to divert patients to ration their medications because of a shortage of some chemotherapy drugs.
In addition, ASHP noted that the continued nationwide shortage of ADHD drugs is “a problem for clinicians and patients. ”
The shortage of popular drugs is even more acute, with Mounjaro, the diabetes drug known as the “slimming pill ”, already in dire straits.
In response, Lilly said that the “unprecedented surge in demand ” for Mounjaro and its similar drug Zepbound has led to a shortage in the market, which the company is struggling to cope with.
Lilly is ramping up investments to boost production at Mounjaro and Zepbound in the second half of 2024.
The company said it expects intermittent supply disruptions in the near term due to unprecedented demand.
How to cure the drug shortage
The last major “drug shortage ” in U.S. history occurred in 2014, and it has only been alleviated in the years since.
Since 2021, the drug shortage situation seems to be increasing, and scholars in the field of medical health and economics in the United States believe that the reason for most drug shortages in the United States is the fragmentation of the drug supply chain.
The White House this month proposed spending between $3.26 billion and $5.11 billion over the next decade to help address the nation ’ s drug shortage.
The bill requires approval and funding from the U.S. Congress.
U.S. researchers and policymakers believe that a complete solution to the “drug shortage ” may require changes to the business model of the U.S. pharmaceutical industry, including measures to increase the price of generic drugs to attract more drug manufacturers.
Policymakers recommend giving the FDA more power to access more information about drug shortages and impending shortages.
Currently, the FDA relies primarily on phone calls to manufacturers asking if they can increase their supply to understand the situation.
The American Society of Health System Pharmacists said it is working with the federal government to advise the government on measures to address the drug shortage, including that Congress should require manufacturers to be more transparent on any supply chain issues and encourage more diversity in supply chains.
According to Abramowitz, “The federal government still has a lot of work to do to fundamentally address drug shortages, and the American Society of Health System Pharmacists will continue to engage regularly with policymakers to guide them in drafting and passing new legislation to address drug shortages and continue to advocate vigorously for proven solutions on behalf of our members. ”

The White House has proposed $3.26-5.11 billion to address drug shortages, and US researchers suggest changing the pharmaceutical industry business model.

The FDA needs more power to access drug shortage information and manufacturers need to be more transparent.

Medication shortages have a significant economic impact on healthcare systems, resulting in substantial costs and burdens.

Title:

Content: Prescription drug shortages lead to higher prices

Reporter: Andryanna Sheppard
Published: Updated:
Lea este artículo en Noticias WINK

Millions of people in the United States depend on prescription drugs to manage pain, treat medical conditions, and even to help them stay alive. However, the country’s drug shortage is making it hard for some people to get the medication they need or pay for the drugs that are available.

Federal Drug Administration data shows 90 percent of prescriptions in the US are for generic drugs. According to the National Institutes of Health, most prescription drugs involved in shortages are generic options.

There are currently more than 250 medications on the nation’s prescription drug shortage list, according to the American Society of Health-System Pharmacists. The organization says 2023 marked the worst year for shortages in about a decade.

Jessica Kahn’s two sons were diagnosed with ADD.

“I would say tricky, tricky to navigate,” Kahn described.

For the past year, Kahn said getting their medication has been frustrating.

“I have my list of all the pharmacies. I’ve even driven all the way up north to Walgreens or a CVS, some random place to go pick up a kids’ prescription,” Kahn added.

According to the FDA, prescription drug shortages are often linked to manufacturing and quality problems, delays, and discontinuations. Two drugs used in chemotherapy, Adderall, lidocaine, and amoxicillin are just a couple of the prescription medications on the shortage list.

When drug supplies are low, prices tend to increase. According to the US Department of Health and Human Services, there is a 16.6 percent increase in the price of drugs involved in a shortage. And in some cases, alternative drugs were priced at least three times higher.

“You got to be very conscientious that it might not be available and that it is not an option,” Kahn advised. “No matter how many places you call, it’s not there.”

Beating the prescription drug shortage

Health experts offer these tips:

  • Check the national drug shortage list for your medication and possible alternatives.
  • Don’t wait until your prescription is almost gone to refill it.
  • Check other pharmacies for availability and if you can’t find the generic version, look for coupons or programs that offer payment help. Some patients have reported that they receive additional help to reduce some prescription costs from $100 to $10, it’s not allowed if you are already on Medicare.
  • Websites and apps like GoodRX, RX Saver and WellRX can help you find the cheapest place that has your medication and coupons for it.

Contributors to this news report include: Lindsay Dailey, Producer; Bob Walko, Editor

Copyright ©2024 Fort Myers Broadcasting. All rights reserved.

This material may not be published, broadcast, rewritten, or redistributed without prior written consent.

Medication shortages can increase prices by 16.6 percent and alternative treatments can cost at least three times more.

Technology like AI and data analytics can help predict and address medication shortages, but its benefits and limitations need further exploration.

Title:

Content: Transforming Hospital Supply Chain with AI and Automation

Medical supplies procurement is the second largest expense which constitutes approximately 1/3rd of a hospital’s Total Cost of Operations (TCO). Technology like AI can give precise stock projections so hospitals can purchase the appropriate quantity of medical equipment, devices, and consumables at the right time. Hospitals can reduce operational expenses in the procurement of medical supplies and manage inventories efficiently. This, in-turn, will make healthcare affordable for the patients.

Vivek Tiwari, Founder and CEO of Medikabazaar elaborates on the need to deploy automation in inventory management in hospitals as it helps to cut costs and bring in financial efficiency by saving on the Total Cost of Operations (TCO) and indirectly result in affordable medical bills for the patients.

How COVID 19 has exacerbated the stress on the healthcare system, causing a supply-demand crunch during an emergency situation. What was your role when the pandemic hit? Impact the pandemic has created in the medical supply chain space?

The outbreak of COVID-19 affected almost every business and healthcare, no matter how badly affected, has been up-front and centre of the world’s response in fighting the pandemic. Initially, there was a pressing need for medical equipment and supplies like ventilators, infrared thermometers, PPE Kits, masks, sanitizers etc., the use of which is now more widespread than before with extremely erratic demand-supply patterns across the country. This led us to create one platform which enrols both suppliers and customers of COVID-19 supplies, so we could aggregate accordingly. We devised the COVID Combat Collaboration Platform which brought together the COVID-19 product buyers, suppliers and experts on a single platform to address the huge demand-supply gap and host relevant and reliable information related to this disease.

During the second wave, when the oxygen crisis arose, we procured, delivered and installed oxygen supply systems like oxygen concentrators across India. As part of Project Breathe, we delivered over 10,000 oxygen concentrators to organisations, corporate and prominent hospitals like CMC Vellore, Apollo Hyderabad and Indore, Motherson and Medicover hospital.

We were involved with every stage of the Covid-19 era, right from incorporating modern testing booths at hospitals, installing beds at government recognised COVID centres, to supporting vaccination with VACCICOOL, our proprietary cold-chain vaccine transportation solution and ICU packages designed for COVID patients (adults and children).

Many healthcare digital platforms are coming up in the B2B space. How have you changed the Indian medical supply chain segments, if you can specify trends and changes you have brought into this segment?

While there are many emerging healthcare B2B digital platforms, we offer much more than just a marketplace in the form of our technological product offerings. There are multiple factors that differentiate us from every other competitor in the market.

Our marketplace is dedicated to making healthcare procurement easier, smarter and more efficient for hospitals and medical establishments, which would in turn help them provide care facilities at better prices for patients. The marketplace started with a few thousand products, but now hosts the largest catalogue of medical, dental and veterinary supplies, consumables, equipment and other devices, running up to more than 700,000 SKUs, serving over 18 countries, more than 200,000 customers.

We have successfully delivered over 500 million units to more than 20,000 pin codes across India and connected over 200,000 medical establishments and healthcare professionals globally.

As for costs we help hospitals unlock savings of up to 30 percent with smart-decision making tools like VPO and the patent-recognised AI-ML based inventory management system VIZI. We identify AI has a emerging technology opportunity that can benefit the businesses and healthcare organisations. We are developing cutting-edge research and technology to leverage these opportunities and help businesses. We are into conducting research, applying AI to products and to new domains, and developing tools to ensure that we leverage technology to transform the industry. VIZI and VPO have led to savings in many hospital chains like Jaslok Hospital, Fortis Hospitals, Wockhardt Hospitals, Sir HN Reliance Foundation Hospital, Apollo Hospitals, Artemis Hospitals and Max Healthcare.

With the help of finance partners, Medikabazaar is assisting healthcare providers set up hospitals with smart and easy payment options like revolving credit, no cost EMI, long term asset financing and more. And with our asset lifecycle management service MBARC, service thousands of equipment with our team of 100+ engineers.

Hospitals procure at cheaper rates, but patients are always charged with more margins. How do you see this?

Although hospitals provide a significant humanitarian service where they cure people from life-threatening diseases, they are also like companies with common operational expenses such as staff salaries, debts, etc. Medical supplies procurement is the second largest expense which constitutes approximately 1/3rd of a hospital’s Total Cost of Operations (TCO).

The reason for such high operational costs in procurement is due to offline supply chain systems which are still utilised by Indian healthcare facilities. Lack of channels for gaining product information, the limited scope of comparing them along with restrained communication lines between manufacturers and hospitals are some of the main limitations of offline procurement.

These disadvantages result in uninformed purchases by hospitals where they end up buying mid-quality supplies at disproportionate prices. This in turn severely affects patient care. Additionally, as hospitals purchase supplies at high prices, patients have to bear expensive medical bills making healthcare unaffordable for many in a country like India.

Automation of medical supplies: How does it help in Total Operational Cost (TOC) of a hospital? Can you explain to us how your procurement platform impacts the operating cost of hospitals, why do you think tier II and III hospitals should adopt online procurement of medical supplies?

Hospitals have an established and conventional procedure to procure their medical supplies where the purchase manager searches and reviews potential vendors. After the vendor is selected, hospitals contact them to inquire about their required supplies, negotiate prices, and then procure them. Such an offline procurement process can be complicated and costly.

The objective of medical establishments should be to make the procurement process qualitative, cost-effective which can allow them to save on their Total Cost of Operations (TCO) and indirectly result in affordable medical bills for the patients.

Since there is a lack of automation in inventory management, hospitals find it difficult to manage their inventories due to an erratic demand of medical devices for patient care.

With the integration of AI in our patented application, VIZI, we provide hospitals with precise stock projections so that they can purchase the appropriate quantity of medical equipment, devices, and consumables at the right time. This way they can reduce their operational expenses in the procurement of medical supplies and also manage their inventories efficiently without having to face excesses, shortages, and expiries in stock.

Our largest online catalogue of medical supplies and equipment that hosts over 700,000 SKUs of medical devices, equipment, and consumables, hospitals can choose their required supplies. With us acting as a single point of purchase, hospitals don’t have to contact multiple vendors and handle numerous quotations which save them valuable time and transactional costs. This way, medical establishments can save significantly in their operational expenses thus in-turn making healthcare affordable for the patients.

In India especially, medical facilities in tier-2, 3 cities, and remote locations can get their supplies via our efficient last-mile delivery, something which fragmented offline distribution systems have failed to achieve. Our online platform also provides flexi-finance options such as zero-cost EMIs and rolling credit limit for easing the payment process for healthcare facilities, thereby ensuring better accessibility and availability of medical supplies in tier-II and III hospitals.

What transformation will UK's CDC group new investment bring into Medikabazaar?

CDC’s investment in Medikabazaar will help to streamline the medical supply chain in India, resulting in improved availability of a wide assortment of medical supplies, transparent pricing and lower search costs for small providers. In turn, such products and services would enable these providers to meet the health needs of smaller groups and communities that live beyond large cities. Currently, about 50 percent of our sales are to smaller hospitals and nursing homes, and around 60 percent of the medical establishments that we serve are based outside metro cities.

The new investment is also helping augment our ability to pre-empt any further threat from another wave of COVID-19. Following the recent launch of our ICU packages for adults and children, CDC’s involvement will accelerate our effort to help medical establishments rapidly augment critical care facilities, in preparation for any furtherpandemics or health emergencies. Over and above their investment, we will also benefit greatly from CDC’s sector expertise to support us in scaling our operation across the country to deliver greater variety of essential medical supplies at affordable cost to more customers.

What are the key technologies trends that are increasingly changing the medical supply chain and how it will help in bridging the accessibility and affordability gap?

Supply chain management is one of the largest expensive business functions for healthcare service providers. One of the most effective ways to manage the healthcare supply chain is by using emerging technologies. Some emerging technologies that can impact the healthcare SCM include Intelligent AI and Analytics, Internet of Thing (IoT), Blockchain, and 3D Printing.

The use of AI in areas such as decision support for traditional inventory management has changed the way healthcare providers used to manage, interpret and analyse the data that they collect from various sources. Data analytics has shifted from descriptive to predictive and prescriptive analytics, which allow them to predict future events and decide the next course of action based on that intelligence.

Internet of Things (IoT)-enabled devices are revolutionising remote monitoring in the healthcare sector. Efficient remote monitoring of patients helps in reducing the length of hospital stays and prevents re-admissions. IoT also has a major impact on reducing healthcare costs significantly and improving treatment outcomes.

Blockchain can help healthcare providers in tracking and tracing the supplies remotely, efficiently and securely. Blockchain can also provide visibility and traceability of products across the value chain – right from the raw material provider to manufacturers to healthcare providers with detailed information about every step, without risks of data tampering.

With the help of 3D printing technology, it will soon be possible to produce products in mass, with the added functionality of adding personalisation. Healthcare is one of the sectors that can immensely benefit by adopting the 3D printing technology for various surgical items. 3D printing technology has the power to streamline the supply chain with mass production for quality care.

Follow and connect with us on , Facebook, Linkedin

Sponsored Stories

      Partners:

KPIs for medication shortage mitigation strategies include waiting time reduction and improved patient access.

Title:

Content: 110 KPIs Exposed in the Policy Address! What are the consequences of blackspots and waiting time?
Author: The Sword
Published: Updated:
Chief Executive Li Jiachao promised during his election campaign that all departments would submit "Key Performance Indicators" (KPIs) within 100 days of taking office. He released his first policy address in office today (18). The Appendix lists 110 indicators covering different policy areas and items, including the number of major rat infestation black spots to be reduced by at least half by the end of 2023. The final year of the term will be reduced to about 4.5 years, and the Civil Service Penalty Scheme will be introduced in the second quarter of 2023, among other things.
This paper summarizes key indicators in various policy areas.
Is the default KPI "mission must be achieved", and will there be consequences if it is not achieved?
Government sources said that it would be difficult to understand the difficulties, whether it was a problem with the system or a lack of senior officials, "it is difficult to have a one-size-fits-all effect", at least to clarify the policy indicators.
In the fight against health blackspots:
- The number of major rat infestations will be reduced by at least half by the end of 2023;
- The Housing Authority conducts about 500 joint cleansing operations with different stakeholders in its public housing estates each year.
In terms of housing land:
- introduce a Bill to the Legislative Council in 2022 to amend five development-related laws, so as to reduce the time required for non-large-scale projects to produce "cooked land" from the current minimum of 6 years to about 4 years, while large-scale projects can be reduced from about 13 years to about 7 years;
- Assuming that new PRH flats will be added in the future, the average applicant and the number of recovery flats available for allocation to the Waiting List each year will remain at the current level, reducing the "Comprehensive Waiting Time for Public Housing" to about 4.5 years in 2026-27.
Chief Executive Li Jiachao. (Photo)
New measures to be introduced next year to manage poorly performing civil servants
In his speech, Mr Li said that the Chief Executive ’ s Commendation Scheme would be launched next year.
The target is to be launched in the second quarter of next year. The Government will formulate measures to enhance the efficiency and effectiveness of the management of underperforming staff and consult the Public Service Commission on the proposed measures in 2023 before implementing them.
75% of specialist out-patient patients complete registration and drug collection within 2 hours
Among the indicators, special mention is made of the need to improve specialist out-patient services in public hospitals:
- Reduce by 20% the waiting time of the 90th percentile for HA ’ s specialist out-patient clinics to stabilize new cases in 2023-24
- Improve patient access to HA specialist out-patient clinics with a target of 75% of patients by 31 March 2023
(a) Complete the consultation process from registration to doctor within 60 minutes
(b) Complete the process from registration to collection within 120 minutes
Construction Accident Rate Reduced by 10%, Convenient Usage Doubles Next Year
On occupational safety, there are two requirements:
- reduce the five-year average industrial accident rate per 1,000 construction workers by at least 10% from 29.8 in 2021 to 26.8 in 2026;
- Assist at least 50% of the injured employees in the construction industry who participated in the Pilot Rehabilitation Programme to recover within 5 months after starting treatment by 2023.
The Government is committed to promoting "smart and convenient" applications and has set two major objectives:
- The annual usage of Smart Convenience (total number of transactions) doubled from 5 million in 2021 to 10 million in 2023 and increased to 17.5 million in 2025;
- Promote the adoption of "Smart Convenience" in all government departments by 2025 to provide convenient and one-stop electronic services.

Implementing a "Universal Health Insurance Cost Distribution Target System" and a "Drug Supply Information Platform" can help track and manage drug shortages.

Title:

Content: The lack of medicine continues to burn!
The Ministry of Health and Welfare has proposed a short, medium and long-term strategy to deal with the current 5 coping mechanisms.
Journalist Yen Zhenzhen / Taipei Report
According to the Ministry of Health and Welfare, the shortage of drugs is not a single factor, but includes supply problems, manufacturing problems, clinical demand factors, uneven distribution of drugs, drug use habits and drug prices. In addition to dealing with the relatively high clinical demand items, it is properly allocated to all levels of medical institutions and pharmacies to fully meet the needs of clinical end-use drugs.
This is an advertisement, please continue reading.
In the face of the shortage of drugs, Wang said, the existing health insurance uses five major coping mechanisms, including 1, a single processing window, a dedicated person to help deal with the problem of drug purchase, and contact the Food and Drug Administration to put relevant information on the website of the NHI. (4) Drug price adjustment mechanism that does not meet the cost can be re-checked according to the way of raising the price of special drugs; (5) Alternative drugs can still declare the cost, if they are not irreplaceable, they can be replaced at the same price or lower than the original prescription drug price.
In addition, Wang pointed out that in the face of the international epidemic, the Russian-Ukrainian war, and labor shortage, drug shortage is a problem facing all countries. In order to strengthen the stable supply mechanism of drugs in China, the Ministry of Health and Welfare continues to actively respond to the short-term strategy to solve the problem of drug shortage. The Food and Drug Administration (FDA) and the pharmaceutical industry have made every effort to actively arrange production lines, strive for early import, increase production / import quantity, and properly distribute to all levels of medical institutions and pharmacies to fully meet the demand for clinical end use drugs.
In addition, to properly handle the issue of drug price adjustment, the Central Health Insurance Administration of the Ministry of Health and Welfare intends to implement the "Universal Health Insurance Cost Distribution Target System (DET)" in April this year, which will adjust the number of drug prices and adjust the quota in a suitable manner, taking into account factors such as the epidemic, the Russian-Ukrainian war and inflation.
In terms of medium-term strategy, Wang said that he will establish a permanent drug shortage treatment center and optimize drug supply information transmission.
In order to speed up the handling of drug shortage incidents, we will adopt dedicated personnel and cross-departmental cooperation to develop drug shortage prevention policies to prevent drug shortage in advance, strengthen cross-departmental data integration and proactive monitoring to detect drug shortage incidents at an early stage, and intervene early through cross-departmental cooperation to stabilize drug supply.
At the same time, the Food and Drug Administration (FDA) continues to disseminate drug supply and alternative drug information through various channels. In addition to posting on the “Drug Supply Information Platform ”, the FDA will notify medical institutions and pharmacies through VPN, and weekly letters to relevant medical associations and public associations to inform members. Management system.
In the long-term strategy section, it includes reviewing the current health insurance drug pricing policy and encouraging the production of domestically manufactured generic drugs.
Wang Bi-sheng pointed out that in the review of the current health insurance drug price policy, including the development of the price protection of indicative drugs, drug price review for the lack of drugs; start the review of drug expenditure target (DET), plan the establishment of a risk control mechanism, plan the national unified procurement trial plan; comprehensively review the health insurance drug price policy, give an appropriate price protection mechanism for necessary drugs, and also target the patent period. To encourage the production of domestic manufacturers to ensure that when there is a shortage of original pharmaceutical products, there are domestic famous drugs to respond.
Wang also stressed that the Food and Drug Administration has set up a "Drug Supply Information Platform" (https: / / dsms.fda.gov.tw /), reporting hotline (02) 27878249. If medical institutions and pharmacies have any shortage of drugs, they can go to the platform for enquiry or notification, and the department will deal with it immediately.
This is an advertisement, please continue reading.

Constructing centralized production bases and promoting review and approval of shortage drugs can help address drug shortages.

Title:

Content: 【 Printing 】
2023 shortage of drugs reported information has been fully dealt with
Related LINKS http: / / www.CRNT.com 2024-03-14 15: 33: 32
Beijing, March 14 / Xinhua News Agency reported that the reporter learned from the National Health and Health Commission on the 13th, the national, provincial, municipal and county four shortage drug classification system gradually improved and effective operation, 2023 shortage drug reporting information has been fully addressed, and the temporary import work of clinically urgent drugs is done.
It is understood that in the near future, the national and provincial shortage of drug supply guarantee work will discuss the mechanism of various units to ensure the supply of stable prices as the focus, and continue to improve the classification of shortage of drugs to deal with the ability to deal with, multi-dimensional improvement of shortage of drug information monitoring.
The National Health and Health Commission relies on the national public medical and health institutions shortage of drug information direct reporting system and other monitoring conditions to carry out monitoring and early warning and regular reporting.
The State Medical Insurance Bureau continuously monitors the national shortage list of drugs and clinically necessary drugs that are vulnerable to shortage, focusing on the abnormal high prices and distribution data of the listed drugs.
The National Drug Administration continues to collect information on the production supply and shutdown reports of shortage of pharmaceutical products.
The Ministry of Industry and Information Technology relies on the shortage drug production supply monitoring and early warning platform to carry out dynamic monitoring and analysis.
The Ministry of Commerce organized some large pharmaceutical wholesale and retail enterprises to pay close attention to the supply and demand situation of pharmaceutical products.
At the same time, the whole chain guarantees the stable supply of shortage drugs.
The National Drug Administration continues to promote the review and approval of national shortage drug list varieties, and carries out the basic information labeling and data management of shortage drugs.
The State Medical and Health Insurance Bureau fully implements the policy of online procurement of shortage drugs, and explores the centralized procurement of shortage drugs.
The Ministry of Industry and Information Technology continues to support the construction of centralized production bases for small varieties of drugs, and establish regular shortages of drugs at the central and local levels.
The Ministry of Ecology and Environment takes flexible enforcement action to help enterprises rectify the situation in a timely manner if the environment of the enterprises involved in the production of pharmaceutical raw materials or preparations violates the law.
The SASAC of the State Council continues to promote state-owned enterprises to fulfill their social responsibilities in the supply of shortage drugs and play the function of "cistern".
The National Post Office continues to promote the construction of a comprehensive postal service platform, supporting the postal group to give full play to its network advantages and continuously improve its medical distribution service capabilities.
In addition, strengthen the enforcement of illegal acts.
The General Administration of Market Supervision investigates and punishes illegal acts such as monopoly in the field of pharmaceutical products according to law, and plays a warning and education role in major typical cases.
The General Administration of Taxation further increased the investigation and punishment of tax violations by some pharmaceutical enterprises, and standardized the tax order in the pharmaceutical field.
According to the clues of the problem and illegal facts, the National Medical Insurance Bureau talked about the relevant pharmaceutical companies to reduce the level of drug prices involved, and block the chain of benefits of manufacturing shortages and monopoly price increases.
【 Printing 】
Related News:

The National Health Commission and State Medical Insurance Bureau monitor and track drug shortages and prices.

Waiting time reduction and improved patient access can be used as KPIs to measure mitigation strategy effectiveness.

Patient registration and drug collection times can be used as a KPI to measure mitigation strategy effectiveness.

Medication shortages require a multifaceted approach, including improved manufacturing, quality control, and industry transparency.

Technology and KPIs can help predict, address, and evaluate medication shortages and mitigation strategies.

The EU has proposed a voluntary solidarity mechanism to address medication shortages, including an early warning system and joint drug procurement.

Title:

Content: Brussels is planning for EU countries to share vital medicines and take emergency measures to avoid a repeat of shortages that hit the bloc a year ago.

The European Commission is proposing a “voluntary solidarity mechanism” requested by France and Germany and an early warning system flagging when drugs become scarce, according to draft proposals seen by the Financial Times. If insufficient donors come forward, EU capitals will be allowed to tap into an EU-funded stockpile set up during the Covid-19 pandemic and take other emergency measures.

In December and January western countries suffered a shortage of antibiotics including penicillin and amoxicillin, and painkillers such as paracetamol, especially in medicines used by children.

Among the emergency measures floated to prevent a repeat of that crisis, the commission could allow the extension of a drug’s shelf life, fast track approvals of alternative suppliers and support production increases.

Brussels will also encourage joint procurement of drugs from 2024 and medicine swaps with countries in the southern hemisphere, where peak winter demand happens at a different time.

The commission will draw up guidance for national stockpiles in 2024 and establish a Critical Medicines Alliance bringing governments, industry and civil society together. The commission declined to comment.

Three-quarters of countries reported a worsening of drug shortages in 2022, according to an industry survey. EU manufacturing is heavily reliant on imported active pharmaceutical ingredients from China and India.

Rising demand and disruption to supply chains have been compounded by inflation hitting the production of generic drugs, which typically sell at much lower prices than branded versions.

France has been actively encouraging the reshoring of basic medicine supply, with a giant paracetamol factory set to open in the country next year.

The EU is discussing whether to provide more funding for domestic production.

The commission’s proposal is scheduled to be approved on October 25 and could still change. Initially non-binding, it could lead to a Critical Medicines Act, with Brussels drawing up a list of vital medicines by year-end.

The commission also urges member states and the European parliament to approve its overhaul of pharmaceutical legislation, put forward in April. It includes plans to take control of drug production in the event of a public health emergency, a requirement for stockholders to inform Brussels of supply levels and for manufacturers to give early warnings of shortages.

An analysis by the European Medicines Agency and the commission found that unless there is unexpected demand the EU should avoid an antibiotics shortage this year.

“The information available today suggests that — if demand in the coming winter season does not differ significantly from the demand of recent years — the supply to the EU of key antibiotics seems to generally match demand,” the analysis said.

“However, this depends strongly on the compliance of industry with their legal obligations to ensure supply and their ability to adapt.”

Copyright The Financial Times Limited 2023. All rights reserved.
Reuse this content (opens in new window) CommentsJump to comments section

Follow the topics in this article

The EU will set up an early warning system for scarce drugs and implement emergency measures.

The Ministry of Health has allocated 240 billion rubles for drug provision and introduced a labeling system for real-time tracking.

Title:

Content: The Ministry of Health told what they did to prevent a shortage of drugs
The head of the Ministry held a meeting with representatives of pharmaceutical companies
The head of the Ministry of health Mikhail Murashko said that the government has made decisions that will help to avoid a shortage of drugs.
He said this at a meeting with representatives of pharmaceutical companies, which took place on April 18.
In particular, an advance of 240 billion rubles was made within the framework of compulsory medical insurance, which is up to 80% of all expenses of medical organizations for drug provision, - the Minister of Health said. - This allows pharmaceutical manufacturers to clearly plan the production and supply of drugs.
Today, thanks to the labeling system, we see the movement of medicines, their remains in each region and the introduction into civilian circulation in real time.
This allows us to determine with high accuracy the positions at which subsequently reduced availability is possible, and to take the necessary measures in advance.
Murashko also noted that in the near future, the possibility of using data on the pharmaceutical substance previously included in the registration certificate of other drugs during the registration of a medicinal product will be worked out without the need for additional examinations.
This will simplify the registration process.
• LIKE0
• LAUGHT1
• SURPRISION0
• RIGHT0
• FURNITURE0
Did you see the typo?
Select a fragment and press Ctrl + Enter
� � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � �
� � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � �

The registration process for medicinal products will be simplified.

The National shortage drug classification system has been improved and urgent drugs temporarily imported.

A mechanism for stable drug prices is being discussed and drug information monitoring has improved.

The Ministry of Health plans to establish a "shortage of drugs center" and set a "floor price" for drugs.

Title:

Content: There is a shortage of Chinese and Western medicines in the country, and there is a shortage of Punacao, the antibiotic ammonicillin, the acid-making agent magnesium oxide, and so on.
At present, the Ministry of Health and Welfare plans to establish a "shortage of drugs center", and the National Health Insurance Administration also invited the medical community, pharmaceutical companies, etc., to meet, it is generally deduced that the price of drugs is low, the lack of profit incentives, resulting in a reduction in the production willingness of pharmaceutical companies, which directly affects the stable supply of drugs.
Cai Mingzhong, chairman of the Kuomintang Medical Committee, said that in order to solve this problem, Shi Chongliang, director of the National Health Insurance Administration, proposed to ensure the necessary "directive drugs", and should set a "floor price" according to the prescription drugs to protect the basic profits of the drugs and avoid impacting the market supply.
He observed that Taiwan's "prescription drugs" in the past 1 or 2 years have set a floor price (at least 2 yuan or 1.5 yuan), the results are good, such a model should be transplanted to the common needs of the public "indication of drugs" items, the same set of "floor prices", to improve the industry's production willingness, is indeed one of the necessary measures to avoid market shortage of drugs, should be supported.
On March 18, 2019, the National Health Insurance Administration issued a press release saying that since the second generation of health insurance is on the road, the "Drug Expenses Target System" (DET) has been piloted in accordance with the law. A small number of pharmaceutical companies claim that the price of health insurance is not enough to cover the cost. The NHI is willing to continue to communicate and actively review the calculation formula of DET on the premise of ensuring the rights and interests of the public with drugs, so that the pharmaceutical industry has a reasonable living space.
However, Tsai Ming-chung believes that even if DET continues to carry out, the effect of suppressing the continuous expansion of drug costs will gradually become blunt with time. As for the cost of DET, it will become a burden for the medical sector.
# Drugs # DET # Lack of Drugs # Floor Price # Health Insurance Department

The EU has created a strategic supply of scarce drugs and obliges manufacturers to guarantee supply.

Title:

Content: Gazeta.ru on desktop
for quick access
Install
Not now
Financial Times: The European Union has decided to create a strategic supply of scarce drugs
The European Union (EU) intends to create a strategic supply of medicines and oblige manufacturers to guarantee their supply.
This is reported by the Financial Times with reference to the representative of the European Commission (EC).
According to the interlocutor of the publication, the shortage of pharmaceuticals is a “systemic challenge ” for EU member states, so the EC intends to ensure“ strategic autonomy ” in the supply of essential drugs, such as paracetamol and penicillin.
The FT source also said that in the near future the European Commission will introduce a law that will allow “to ensure access of all patients in need to medicines. ”
For this purpose, it is planned to “introduce stricter obligations for suppliers, improve the availability of information on drug stocks, and require earlier notification of shortages. ”
According to the European Commissioner for Health Stella Kyriakidis, discussion of these measures with representatives of the industry has already taken place.
Earlier it was reported that the French authorities banned the online sale of paracetamol until the end of January 2023 due to problems with the supply of the drug.
According to a press release from the French government, the tense situation with the supply of drugs based on paracetamol persists in France for more than six months.
This also applies to drugs intended for children.
Share:
Downloading
Found a bug?
Close

A law will be introduced to ensure patient access to medicines, with stricter supplier obligations and earlier shortage notifications.

Title:

Content: Gazeta.ru on desktop
for quick access
Install
Not now
Financial Times: The European Union has decided to create a strategic supply of scarce drugs
The European Union (EU) intends to create a strategic supply of medicines and oblige manufacturers to guarantee their supply.
This is reported by the Financial Times with reference to the representative of the European Commission (EC).
According to the interlocutor of the publication, the shortage of pharmaceuticals is a “systemic challenge ” for EU member states, so the EC intends to ensure“ strategic autonomy ” in the supply of essential drugs, such as paracetamol and penicillin.
The FT source also said that in the near future the European Commission will introduce a law that will allow “to ensure access of all patients in need to medicines. ”
For this purpose, it is planned to “introduce stricter obligations for suppliers, improve the availability of information on drug stocks, and require earlier notification of shortages. ”
According to the European Commissioner for Health Stella Kyriakidis, discussion of these measures with representatives of the industry has already taken place.
Earlier it was reported that the French authorities banned the online sale of paracetamol until the end of January 2023 due to problems with the supply of the drug.
According to a press release from the French government, the tense situation with the supply of drugs based on paracetamol persists in France for more than six months.
This also applies to drugs intended for children.
Share:
Downloading
Found a bug?
Close

The European Commission proposes shortening drug evaluations from 210 to 180 days, but NGOs oppose it, citing insufficient time for safety checks.

Title:

Content: French health groups put forward proposals to limit the damage of worsening drug shortages

Medicines such as cough syrup, lozenges and ointment are seen on a table in an apartment in Berlin, Tuesday, December 20, 2022. Copyright Stephanie Pilick/dpa via AP
Copyright Stephanie Pilick/dpa via AP
By Lauren Chadwick
Share this articleComments
Share this article

Pharmaceutical companies’ lack of transparency leads to rising drug prices and less control over public resources, the group of health organisations say.

ADVERTISEMENT

A group of French organisations have called for more transparency from pharmaceutical companies as drug shortages increase.

In a joint report, 14 civil society organisations outlined their recommendations to solve a “situation that has only worsened” since 2018.

The French medicines regulator signalled 4,925 drug shortages in 2023, compared to 3,761 in 2022 and 2,160 in 2021.

A 2024 survey from France Assos Santé, which represents patients, found that 44 per cent of people in France said they had faced a drug shortage this year.

One of the pharmacy unions in France has even planned a strike at the end of the month over drug shortages and what they say is worsening access to care.

Each health organisation contributed an article with recommendations for dealing with the drug shortages.

The League Against Cancer urged complete transparency on drug shortages and potential substitutions for health professionals.

They also called for monitoring of medicine stocks and their location in the country to guarantee equal access.

The organisation found in a survey published in February that 78 per cent of health professionals in oncology had been faced with a drug shortage.

Drug shortages or delays have led to anxiety among cancer patients, lost time, and worsening symptoms, the organisation said.

France Assos Santé, meanwhile, wrote that an urgent response should not be to support “the industrial sector which bears serious responsibilities” for abandoning the production of less profitable drugs, relocating drug production, and keeping insufficient medicine stocks.

They would like any cost increases justified by production costs or the risk of withdrawing a drug from the market due to it being unprofitable. They called for cost evaluations to be made public.

Their concerns also range from the use of public money to bring drug production to Europe to new government plans to prevent shortages.

Some changes at the EU level criticised

Last year, the European Commission announced several measures to reform the pharmaceutical industry and address critical drug shortages.

The European Parliament went on to adopt a position on pharmaceutical reform last month, that included “incentives for innovation” and an effort to limit overuse of antibiotics.

The non-profit organisation Prescrire, which focuses on information about medicine, wrote in a chapter they contributed to the report that while some of the European Commission’s measures were welcome, others were concerning.

One of the many measures they rejected included the Commission’s proposal to reduce the number of days of scientific evaluation of drugs from 210 to 180, which they said was necessary time rather than an “administrative obstacle”.

While the NGO welcomed some measures such as government drug shortage prevention plans, it said the Commission should allow EU states to require pharmaceutical companies to have safety stocks of medicine and sanction those that do not respect them.

ADVERTISEMENT

French consumer organisation UFC-Que Choisir and the European Consumer Organisation (BEUC) said that they had hoped MEPs would shorten the length of time for “data protection” to allow generic medicines to be marketed more quickly.

Instead, MEPs approved shortening the period to 7.5 years, “which is almost the same duration as the current 8 years [yet] within the framework of the text adopted by Parliament, companies can gain additional months of protection under certain conditions to reach a total of 8.5 years,” UFC-Que Choisir said.

Share this articleComments

You might also like

The EU may require pharmaceutical companies to hold safety stocks and has shortened data protection for generic medicines to 7.5 years.

The Ministry of Health has proposed a strategy to address drug shortages, including coping mechanisms and a drug price adjustment.

The FDA requires manufacturers to report supply interruptions and production disruptions.

Title:

Content: FDA gave instructions to pharmaceutical manufacturers to prevent the risk of defects
The FDA has released a draft guideline that will allow pharmaceutical manufacturers to more accurately report disruptions to the production of drugs and APIs.
In particular, it specifies who should contact the regulator in case of a failure in production and on which products it is necessary to transmit information.
The U.S. Food and Drug Administration (FDA) has issued draft guidelines to pharmaceutical manufacturers to prevent the risk of flaw.
According to the instructions, they will notify the agency of changes in the manufacturing process of drugs, biological products or active pharmaceutical ingredients (API).
In the United States, FD & C. It requires manufacturers to notify the agency of interruptions in the supply of products or APIs.
The FDA ’ s new guidelines provide clarifications.
Manufacturers must submit a notice to the FDA at least six months before stopping drug production, which could lead to their shortages on the market.
If it is not possible to notify the agency six months in advance, it should be done “as soon as possible ”.
If interruptions in production may affect the supply situation, the manufacturer should assess the situation only on the basis of its capabilities.
It should not take into account the capacity of other manufacturers, the amount of product on the market or market demand.
The guidelines also state what specific product or API information manufacturers should report when informing the FDA.
CBS, citing a report from the US Senate, writes that by the end of 2022, the shortage of drugs in the US had reached a five-year peak and affected almost 300 pharmaceutical products.
This is due to the fact that the United States moved production to China, India and other countries.
According to the American Society of Health System Pharmacists, products such as sodium chloride solution, the antibiotic amoxicillin and albuterol inhalation solution are now in short supply.
Nikolay Sokolov
pharmvestnik

The US Senate reported that nearly 300 pharmaceutical products were affected by shortages in the US in 2022.

China has strengthened anti-unfair competition law enforcement in the pharmaceutical industry and issued a plan for medicine development.

Title:

Content: City News
31 / 01 / 2022 10: 02
Mainland strengthens anti-unfair competition law enforcement, shortage of drugs, etc.
Nine departments, including the Ministry of Industry and Information Technology and the State Drug Administration, have issued the "14th Five-Year Plan" medicine.
The development plan of the pharmaceutical industry says that it regulates the market competition order, strengthens anti-unfair competition law enforcement, and resolves to investigate and deal with commercial bribery in the pharmaceutical field.
Unfair competition.
Strengthen antitrust law enforcement in the field of shortage drugs and raw materials, formulate and implement antitrust guidelines in the field of raw materials drugs, according to
Illegal acts such as monopolistic agreements and abuse of market dominance are prosecuted.
The Ministry of Industry and Information Technology said that it is necessary to vigorously promote the research and development of innovative products, focus on new targets and new pharmaceutical products, and actively lead the development of innovative products.
New; continue to promote the dynamic adjustment and access negotiations of medical insurance catalogues, and improve the mechanism for the formation of new drug prices.
The latest planning target is to maintain the average annual growth rate of operating income and total profit at more than 8% by 2025, and the value added accounts for the whole of the country.
The proportion of the Ministry of industry has increased to about 5%; the industrial chain supply chain is stable and controllable, and a number of key common technologies for industrialization have made breakthroughs.
The supply and protection capacity continues to increase, and the supply of major disease prevention and treatment drugs, vaccines, protective materials and diagnostic equipment is sufficient.
The supply of drugs, small varieties of drugs, and drugs that are prone to shortage is stable.
By 2035, the innovation-driven development pattern will be fully formed, and original innovative drugs and "
The number of leading products has increased, and it has become an important source of medical innovation in the world.
During the 13th Five-Year Plan period, the added value of China's pharmaceutical industry above the size of the average annual growth rate of 9.5%, accounting for the proportion of the added value of all industries.
Increase from 3.0% to 3.9%; annual growth of business income and total profit of enterprises above scale 9.9% and 13.8%
. (JT)
(Limited Time Offer) Apply for ETNET Enhanced MQ Mobile Streaming Quote Service and get a $50 voucher!
► Action Now
Popular articles
Financial News
Commentary
WikiProject
【 Limited Time Offer $88 / month 】 Apply etnet Enhanced MQ Mobile Streaming Quote Service and get supermarket $50 voucher
[Investment Preferred] etnet Hong Kong stock information, the most in Hong Kong!
Subscribe to etnet YouTube Channel to enjoy etnet notebook and 2022 calendar card

The plan aims to promote innovative products, adjust medical insurance, and reform drug pricing.

The US faced 323 drug shortages in Q1 2024, including chemotherapy and ADHD medications.

The White House has proposed $3.26-5.11 billion to address drug shortages, and US researchers suggest changing the pharmaceutical industry business model.

The FDA needs more power to access drug shortage information and manufacturers need to be more transparent.

US shortages are mainly caused by a fragmented supply chain, particularly affecting non-patented sterile injectable drugs.

Chemotherapy and ADHD drugs are among those most affected by shortages.

The Hospital Authority purchased paracetamol from the Mainland due to a shortage, introducing non-local drugs.

Title:

Content: Locally
2022-08-02 04: 30: 55
Daily News
The shortage of commonly used pharmaceutical factories has led to the unusual practice of the Mainland and Western Medicine Hospital Authority
Share:
Hospital Authority Director of Cluster Services, Mr Tang Yiu-keng (pictured), pointed out that because of the shortage of paracetamol, the Hospital Authority purchased paracetamol tablets from the Mainland. He pointed out that when the situation is urgent, it is very unusual to use the designated patient drug use plan to introduce drugs. Production to avoid common drug shortages.
As for the earlier switch to the mainland antibiotic "cefoxidine for injection", which was also supplied by the original drug manufacturers, the mainland version was imported to cope with the sudden surge in demand.
The supply situation is stable and the use of the same antibiotics as the original contract has been restored.
Chief Pharmacist of HA, Mr Lee Shing-cheung (first from left), said that the percentage of pharmaceutical products purchased by HA in China remained stable at about 3%, with no significant increase.
Mr Tang reiterated that the Bureau will adhere to four major principles when purchasing drugs, including whether the drugs are registered and GMP regulated by the Department of Health; ensure product specifications by means of medicines; pass non-proprietary drug interchangeability tests and demonstrate bioequivalence to the World Health Organization (WHO) requirements; and give priority to the use of drugs with English drug names on the label.
Privacy Protection Policy
Please read and accept the following privacy policy and disclaimer carefully. By clicking "Accept", you agree to and agree to the privacy policy and disclaimer contained in the am730 website.
LEARN MORE
Acceptance

The supply situation is stable, with original antibiotics restored, and the HA follows four purchasing principles, including registration.

Drugs must pass non-proprietary drug interchangeability tests and meet WHO bioequivalence requirements.

The HA prioritizes drugs with English labels and requires GMP regulation for purchased drugs.

Taiwan faces a shortage of 131 medicines, including amoxicillin and acetaminophen.

Title:

Content: The Kuomintang group calls on Chen Chien-jen to take over the government's national security crisis
REPORTER WENG Tzu-kun / Taipei Report
The shortage of drugs in the country continues to burn, the Kuomintang Legislative Yuan group today (1) a press conference called on the Tsai government, do not just want to vote all day, more concerned about the people's health rights, if the Minister of Health and Welfare Xue Ruiyuan, the Food and Drug Administration Director Wu Xiumei do not do well, it will be cut off.
The KMT further demanded that the "Drug Deficiency Monitoring Center" be raised to the level of the Executive Yuan, and called on Premier Chen Jianren to take over the management and treat it as a national security level issue.
This is an advertisement, please continue reading.
The Kuomintang group today opened a "shortage of drugs! shortage of drugs! When?" press conference, the general convenor Zeng Mingzong said that the shortage of drugs is a structural problem, health insurance to slash the price of drugs, so that the shortage of drugs crisis expanded, local pharmaceutical companies are more reluctant to produce low-cost drugs.
And some people complained, ran 10 drug bureaus did not receive drugs, beat the table to scolding, so that the community pharmacist pressure is great.
Zeng Mingzong pointed out that, for example, muscle relaxants reported a shortage of drugs on March 8, 2021, compound antibiotics, anti-fever pain tablets reported a shortage of drugs on June 6, 2022, blood pressure drugs reported a shortage of drugs on August 25, 2022, blood lipid-lowering drugs reported a shortage of drugs on August 26, 2022. In addition to the election, Tsai's government also cares about the health of the nation's people.
Zeng Mingzong said that the Kuomintang group humbly asked the Tsai government, the current lack of eggs, water, and medicine in the country, the people are asking the government what is wrong? Impairment! Failure! Please the government to come up with a specific plan to solve the problem of shortage of drugs, and ensure the basic health rights of 23 million people.
Hsieh Ying-yi, secretary-general, says that recent shortages of amoxicillin, acetaminophen, magnesium oxide, and ibuprofen in primary pharmacies and clinics have revealed that there are 131 medicines out of stock in Taiwan.
She stressed that in order to solve the problem of drug shortage, the community pharmacy has also set up a "mutual aid association" to find drugs in the way of drug exchange.
He bluntly said that this is a serious national security problem, will it make the burden of health care more heavy?
For a long time, the total amount of health insurance system has been driving down drug prices, but international pharmaceutical companies are facing a global shortage of goods, and will not give priority to imports to Taiwan.
When the National Health Insurance Administration wants to solve the unreasonable drug price difference, does it also solve the problem of drug prices that do not meet the cost?
Xie Yifeng also pointed out that on February 11, Xue Ruiyuan urgently convened a meeting on shortage of drugs, and resolved to persuade drug manufacturers to increase production capacity. If it is not possible to increase production capacity, then strengthen the allocation of hospitals and clinics to pharmacies to solve the problem of shortage of drugs.
How does the Ministry of Health and Welfare assist domestic pharmaceutical companies in obtaining raw materials and mass-producing pharmaceutical products?
Not at all.
Shouldn ’ t the Ministry of Health and Welfare convene meetings across ministries, industries, and pharmaceuticals to coordinate and solve problems?
Hsieh Yi-hung lambasted that after the meeting of the Ministry of Health and Welfare, nothing had been done, and such a meeting would not be held.
The Ministry of Health and Welfare will increase the burden of health insurance to 120 million yuan on April 1, which is expected to affect 1.17 million people.
Please ask Chen Chien-jen and the Ministry of Health and Welfare, in the special budget after the epidemic, to allocate 20 billion yuan for health insurance, why do you need to increase part of the burden?
The Ministry of Health and Welfare should first solve the problem of lack of medicines, and do not want to spend money from the pockets of the people.
On March 29, 2019, Wu Xiumei, who is responsible for managing the national drug administration department, held a meeting on “Drug Shortage ”. The results of the expert meeting on the evaluation of the operation and follow-up mechanism of the meeting were only based on the meeting and the meeting was postponed, and the decisions made after the meeting were not implemented.
"Taiwan's lack of medicine is a problem of management." Lai Shibao pointed out that the Ministry of Health and Welfare has constantly justified itself with problems such as rising raw materials and the Russian-Ukrainian war, but the whole world is affected, and Taiwan alone has a shortage of medicine.
In 1999, the US FDA established a “Drug Deficiency Monitoring Center ”, which stipulates that any drug that is less than 6 months in stock must be monitored and taken countermeasures.
Lai Shih-pao points out that the pharmaceutical and medical sectors in Taiwan have long called on the government to do the same.
Lai Shih-pao also suggested that Chen Chien-jen, the National Health Insurance Administration (NHIA) plans to slash the health insurance drug budget by NT $8.1 billion. Please ask the so-called warm and tenacious cabinet to start caring for humanity and solve the problem of shortage of drugs as soon as possible.
In 2016, Tsai Ying-ying told pharmacists at the All-Union Congress of Pharmacists that it was necessary to make medicines available to the people and replace them with social medicines in 2018. The result was still a shortage of drugs.
Yang Qiong said that magnesium oxide mainly treats gastric and esophageal reflux and constipation, is a common chronic prescription drug. Patients need to use drugs every day. Does the government know? In addition, the first-line commonly used antibiotics Ammonicillin and acetaminophen painkillers are lacking, which increases the risk of physical collapse of first-line medical care.
The government does not know what the problem is, and even the drugs have to go back to the original "drug-for-drugs" era, the "drug-for-drugs monitoring center" must be raised to the level of the Executive Yuan, immediately inventory 131 drug categories, immediately replenish, strengthen the monitoring mechanism, so that the people really have drugs available.
Dr. Shen Caiying, spokesman of the Taiwan Pharmaceutical Marketing and Management Association, said with emotion that Tsai Ing-wen had said that the society has drugs available, and the people will use drugs, which of course is also the responsibility of pharmacists.
During the epidemic, the Ministry of Health and Welfare relied heavily on community pharmacies to issue masks and rapid screening to take on the frontline public health mission, but the Ministry of Health and Welfare seemed indifferent to the serious problem of drug shortage.
Shen Caiying questioned the government, according to Article 15 of the "National Health Insurance Drug Price Adjustment Operation Measures", the directive drug is not allowed to have a floor price, but the Director of Health Insurance Shi Chongliang publicly stated that the directive drug should be set a floor price to solve the problem of drug shortage.
Shen Caiying said that for every US dollar used in the United States on the instructions, it can save 6 to 7 US dollars for health insurance, which can save 10.2 billion US dollars a year.
Shen Caiying suggested that the government, to solve the problem of shortage of drugs, please administer according to law, instruct that drugs should not be paid, cancel the daily drug charge, and pay.
The drug shortage center must combine relevant professional groups, patient groups, and pharmaceutical industry to jointly discuss the problem of drug shortage.
In addition, one of the four vice presidents of the Executive Yuan ’ s Commission for Sustainable Development is Minister Weifu. I wonder if the Minister of Weifu has told the Executive Yuan that there is a serious shortage of drugs?
Or do you want the community pharmacy to suffer silently?
This is an advertisement, please continue reading.

International pharmaceutical companies prioritize other countries over Taiwan due to its low prices, exacerbating medication shortages.

The US FDA has a "Drug Deficiency Monitoring Center" that can serve as a model for other countries.

The Ministry of Health and Welfare has failed to address drug shortages, a major concern for healthcare systems.

Medication shortages can cause severe health consequences, including permanent paralysis in multiple sclerosis patients, after the Ministry of Health withdrew support for 14 MS medicines.

Title:

Content: Wednesday 21 November 1445 AH - 29 May 2024 |
Programs
Watch our latest episodes online
Captain Bakhash presents the risks of drug shortage to patients with "multiple sclerosis" and its most prominent consequences
The “Lebanese Society of Multiple Sclerosis Patients ” held a press conference at the“ House of the Doctor ” – Furn El Shbak, during which the President of the Lebanese Doctors Association in Beirut, Prof. Youssef Bakhash, spoke about the dangers of the shortage of medicine and its repercussions on the health of the patient.
He said: “This press conference is being held today on the occasion of World MS Day.
This disease and like any chronic disease, the treatment of its patients falls on the responsibility of the state and the Ministry of Health and this is a national and humanitarian duty to care for these patients as we care for every patient who needs care, treatment or support.
Especially those with chronic diseases such as cancer, diabetes, kidney disease and other diseases. ”
He added: “With regard to MS, science, development and studies have discovered 17 drugs to treat these patients, but unfortunately, only three of the 17 drugs in Lebanon are supported by the ministry.
Today, my speech will revolve around three points, the first point that the Ministry of Health withdrew the support for 14 medicines and kept it on three, including one that makes the Lebanese interior, the voice we want to make is the need to make room in the field to support the largest number of these medicines that enable our patients to recover or at least stabilize their situation. ”
He continued: “The second issue is the continued existence of the drug in a way that meets the needs of these patients because any failure leads to serious consequences, the most serious of which is permanent paralysis.
The third point is the need to organize the distribution of the drug and deliver it to the treatment centers and make sure that the beneficiary is the patient who remains the first and most important goal. ”

The medication shortage affects multiple sclerosis and cancer patients, highlighting the need for organized distribution to treatment centers.

Riluzole, a medication for motor neurone disease, is in short supply, causing patient access difficulties and added distress.

Title:

Content: Health Secretary faces mounting pressure from campaginers to address drug shortages

Campaigners have called for Health Secretary Victoria Atkins to urgently tackle a dire shortage of the only licensed drug available to people living with motor neurone disease.

Health Secretary Victoria Atkins (Image: getty)

Patients have been forced to visit multiple chemists to find riluzole, which slows the progression of the brutal terminal condition by a few months, due to a supply issue that has created a UK-wide stock shortage since September.

One MND sufferer, who did not want to be named, recently had to go to 15 pharmacies before they could get the drug.

Tanya Curry, chief executive of the MND Association, has written to the minister saying: "We are now receiving reports daily from across the country that patients are unable to access their prescribed medicine, with no stock available in pharmacies and no indication of when it will become available.

“Some newly diagnosed patients are being denied their only medication option due to the lack of available supply. This is absolutely not good enough.”

She added: “The lives of people with MND are already limited by this devastating condition. They do not have time to wait, and certainly should not have to spend their precious days fighting to get the medication they deserve.”

Patient Lee Millard said: “We have but one drug, riluzole, for MND currently and anything that risks patients not receiving this one single tablet adds to the distress of day to day life.

“Our main charity, the MNDA, have raised with the Department of Health and Social Care (DHSC) but have received no details of what the issue is nor how it will be resolved. This just adds to the concern.”

A DHSC spokesperson said: “We understand how distressing medication shortages can be, which is why we’ve been working closely with manufacturers to resolve these issues as soon as possible and ensure patients have continuous access to MND medication in the UK.

“We are aware of an issue with one supplier but alternative suppliers should have stock available for patients who require it.

“We are determined to improve the lives of people with MND. That’s why, in November 2021, we committed to spend at least £50million on MND research over five years ending in March 2027.

“It is hoped this will enable faster progress towards treatments for this debilitating condition.”

Become an Express Premium member
  • Support fearless journalism
  • Read The Daily Express online, advert free
  • Get super-fast page loading
Would you like to receive notifications from this site?

The Department of Health is working with manufacturers and alternative suppliers to resolve shortages.

Cisatracurium, crucial for severe pneumonia, is in short supply, increasing the death rate, with no alternative for emergency intubation.

Title:

Content: The shortage of drugs has recently floated on the table, and the Ministry of Health and Welfare has admitted that there are 15 kinds of drugs in China that are seriously out of stock.
Thoracic physician Su Yifeng pointed out that the emergency intubation drug Cisatracurium is an important life-saving drug for patients with "large white lung", and the problem of shortage cannot be ignored.
Unexpectedly, but some netizens questioned him "only fear the world is not messy", Su Yi-feng stressed that Cisatracurium did the third phase of the study, which proved that it can reduce the death rate of severe pneumonia; but the same type of drug Rocuronium recommended by the navigator, there is no third phase of severe pneumonia research, and the reverse acid is the same as high-end, not clinically but believed to be effective.
Dr. Su Yi-feng said in a Facebook post on the 28th that among the 15 missing drugs announced by the Food and Drug Administration, constipation, diarrhea, pain relief, antibiotics, blood pressure, blood lipids, etc., there are alternative drugs to choose from, but the first aid intubation drug Cisatracurium is an important life-saving drug for large white lung, which can reduce the complications of intubation.
In January, Su Yi-feng received a confirmed Taiwanese businessman, and the case appeared to have the severe symptoms of pneumonia commonly known as "big white lung". At that time, it was emergency intubation treatment that saved one life.
He stressed that "the death rate of severe white lung disease will increase due to lack of medication."
Some netizens refuted him, saying that "Cisatracurium is a muscle relaxant, Cis is not the only muscle relaxant that can be used in intubation, especially emergency intubation is almost not used, Cis is out of stock is not news, why alarmist?"
And Cis has been out of stock for a long time, so how to insert the tube and open the knife during this time?
Is there no chaos in the world? "
Su Yi-feng replied, "Have you taken care of the ICU (intensive care unit?)? The drugs are the more complete the better, many hospitals have not entered Roc at all, I have low loyalty to think about the national health as the main, take care of your logic no eggs how not to eat duck eggs eggs on the good, why complain?
Right? "
Su Yifeng today (1) issued an article emphasizing that Cisatracurium, did the third phase of the study to prove that it can reduce the death rate of severe pneumonia, the results of the study were published in the New England Journal.
"Some of the escorts said that I was creating panic, and it was OK to switch to the same type of drug, Rocuronium, the problem is that Rocuronium did not have the third stage of severe pneumonia research!" He also mentioned that no international treatment guidelines for severe pneumonia ARDS dare recommend the use of Rocuronium to save lives. Clinical trial, but I believe it works!
# Medications # Su Yi-feng # Cisatracurium # Large white lung # Lack of medicine

The Cisatracurium shortage significantly impacts patient outcomes and mortality.

Drug shortages can negatively impact pharmacy economies by 20% and harm patient health by limiting access to vital medicines.

Title:

Content: Pharmacies owners in Alexandria: The drug commodity is strategic and the shortage affected the employment by about 20%
A number of members of the Board of Directors of the Pharmacies Owners Division at the Chamber of Commerce in Alexandria stressed that the problem of shortage of many drugs that began to appear recently led to problems and negative phenomena and reflected on the operating economies, in addition to its negative impact on the health of patients mainly.
Moataz Mahmoud
11: 48 AM, Thursday, 20 Jul 23
A number of members of the Board of Directors of the Pharmacies Owners Division at the Chamber of Commerce in Alexandria stressed that the problem of shortage of many drugs that began to appear recently led to problems and negative phenomena and reflected on the operating economies, in addition to its negative impact on the health of patients mainly.
Some added that the drug commodity has a special nature and there is no one to dispense with it, pointing out that the drug market suffers from a real problem that must be intervened to fix it, especially that there are vital medicines and some chronic diseases have become unavailable, which means there is a risk to the health of patients who use them.
Some estimated the rates of negative effects on the economies of pharmacies by about 20% as a result of the shortage of many drugs, which affects their sales, pointing out that the impact of pharmacies remains limited compared to the effects achieved on patients.
Some considered that the drug commodity represents national security and therefore the crisis of drug shortages must not continue and must be resolved quickly, in order to preserve the sector and not collapse, especially as the pharmaceutical sector proved efficient in the stage of facing the new Corona virus pandemic and stood by the Egyptian state at that critical period.
Samir Siddiq: Commodity Medicine Strategy
At the beginning, Dr. Samir Siddik, a member of the board of directors of the pharmacy owners division in the Chamber of Commerce in Alexandria, and the former chairman of the board of directors of the division said that the problem of shortage of many drugs that began to appear recently leads to disasters in the drug market and affects patients negatively mainly.
Siddiq added that there is no individual in Egypt who does not use it, even if this is at the level of the healthy for ordinary aspirin or sparkling, pointing out that this has turned into a real problem experienced by many parts of the system.
He considered that the pharmaceutical market suffers from a real problem that must be intervened to reform this important and vital market.
He explained that there are vital medicines, some of which are specific to chronic diseases, have become unavailable or available in the market, which means that the continued absence of these medicines means the slow death of patients who take them.
He pointed out that the nature of the drug commodity is national security and it is necessary to intervene to resolve it, explaining that the Egyptian Drug Authority should have a role in this matter besides its work as a lecturer for pharmacists and balance errors more than its keenness on the availability of drugs in the markets.
He considered a member of the Board of Directors of the Pharmacies Owners Division in the Chamber of Commerce in Alexandria, and the former Chairman of the Board of Directors of the Division that the crisis of shortage of medicines continues in the markets since 2019, but it has worsened recently and significantly for many varieties.
Samir Siddiq considered that the shortage of medicines affects the sales of pharmacies and their operating economies, pointing out that the lack of availability of these medicines leads to a negative impact on pharmacies by an estimated 20%.
The Egyptian pharmaceutical markets are witnessing a clear shortage in many pharmaceutical items during the recent times, which has been reflected significantly on many dealers in the drug circulation system, from patients, hospitals, production companies and distribution companies to pharmacies, which is the main point and the final link between the producer and the final consumer of the drug.
In turn, Dr. Mohamed Hamed, a member of the Board of Directors of the Pharmacies Owners Division at the Alexandria Chamber of Commerce, explained that the problem of shortage in some medicines suffered by the markets varies from one category to another and from one company to another.
Hamed stressed that the drug commodity represents national security and therefore the crisis of drug shortages must not continue and must be resolved, pointing out that the pharmaceutical sector bore the burden of confronting the new Corona virus and stood by the Egyptian state at that critical period.
He added that pharmacies were suffering with patients during the pandemic, while private hospitals were demanding large amounts for patients per day, and pharmacists made efforts to solve the crisis and alleviate its impact, so medicine should not be increased without compensation.
He considered that some pharmacy chains are one of the reasons for the deterioration of the profession and some of them are a failure, which means that the community and the sector can not rely on large pharmacies alone, but individual and small pharmacies bear the burden of covering the sector as the most widespread and provide technical advice, pointing out that some chains offer discounts to citizens that they got bank loans enabled them.
A member of the Board of Directors of the Pharmacies Owners Division at Alexandria Chamber of Commerce pointed out that the continuation of the shortage of medicines means the aggravation of the problem on patients and for pharmacies, they will not be affected by the shortcomings as much as the effects on patients and therefore the public is the most affected.
He considered that the lack of impact on pharmacies is due to the fact that the shortcomings do not reach to stop companies from producing fully, but some companies manufacture many products and stop producing some of those types as a result of not making profits from them, in contrast, there are other companies may be manufacturing the same product under another brand name and at a different price and make profits and continue to produce it.
A member of the Board of Directors of the Pharmacies Owners Division at Alexandria Chamber of Commerce explained that in such cases the pharmacist dispenses the medicines available to patients and sometimes the doctor has to prescribe them to patients regardless of their prices.

The pharmaceutical sector is crucial for national security, and ongoing drug shortages threaten patients' lives.

Medication shortages can endanger patient lives by affecting vital systems and causing severe health issues.

Title:

Content: -- -- -- / -- -- --
Site Management
They protested Wednesday in front of the Health Ministry.
Primary Immune Deficiency Patients Without Medication For 3 Months
Cream of Salad
• 121
• 0
On Wednesday morning, patients with primary immune deficiency “a rare chronic disease ” protested in front of the Ministry of Health headquarters to provide the medicine“ Aminoglobulin ”, after the numerous correspondence addressed by the ministry without receiving an answer or any response either negative or positive, according to “Daily Shorouk ” President of the Association Manaseri Ali Nasser.
Manaseri explained that the drug has been missing at the level of health centers and hospitals for about 3 months, although it is essential to maintain the stability of the health status of patients and the balance of their immune system, as the lack of it endangers the lives of patients, as well as rot in the respiratory system (lungs) and upper respiratory system (ear, sinuses and throat), as well as rot in the digestive system, skin and other organs. Crabs.
A letter addressed to the Ministry of Health said that patients were hoping to benefit from modern and innovative treatments for their disease such as subcutaneous drugs, which is a home treatment unlike what is currently practiced through continuous intravenous injection or even the provision of a pump implanted in the body.
Representatives of the protesting patients were received by the Director of Pharmacy at the Ministry, who was assured of the arrival of initial shipments of the drug by the beginning of next week and received at the level of the central pharmacy of hospitals on Sunday, and explained the most important reasons that led to the scarcity and related to the developments of the global market.
Add your comment
All fields are required, and your email will not be published.
Please adhere to the site policy in the comments.
Your comment has been sent for review, it will be published after approval!
COMMENTS
0.
Excuse me! Excuse me!
There is no content to show!

The shortage of medication can last months, making initial shipments crucial for patient health despite potential alternative treatments.

Medication shortages affect various drugs, including Cisatracurium, for which alternatives are available for some.

Title:

Content: The Ministry of Health and Welfare has admitted that there are 15 types of drugs in the country that are seriously out of stock.
Dr. Su Yi-feng said in a Facebook post on the 28th that the Food and Drug Administration announced 15 types of missing drugs, including constipation, diarrhea, pain relief, antibiotics, blood pressure, blood lipid reduction drugs, barely can also have alternative drugs to choose, but the first aid intubation drug Cisatracurium is an important life-saving drug for large white lung, can reduce the complications of intubation, "this really can not be ignored!"
Su Yi-feng received a confirmed Taiwanese businessman in January, and the case showed severe pneumonia, commonly known as the "big white lung" symptoms, which at that time was an emergency intubation treatment to save a life.
Su Yi-feng also warned, "I can only ask you to be careful not to be serious about large white lung, the death rate will increase due to lack of medicine."
There were 9,908 new local cases of COVID-19 in China on the 28th, a decrease of 7,069 cases, compared with the 16,911 reported on Tuesday, a decrease of 41.4%. At the same time, 212 new cases of foreign migration and 40 deaths were added.
Luo Yijun, a spokesman for the Central Epidemic Command Center, said that it is expected that the number of confirmed cases will be higher than today's, and will fall between 15,000 and 20,000, and the impact of fake crowds on the rise of the epidemic is expected to be observed on Saturday.
# Drugs # Big White Lung # Su Yifeng # Out of Drugs # Out of Stock

A steady supply of Cisatracurium is needed to reduce intubation complications and mortality rates in severe pneumonia.

Title:

Content: The Ministry of Health and Welfare has admitted that there are 15 types of drugs in the country that are seriously out of stock.
Dr. Su Yi-feng said in a Facebook post on the 28th that the Food and Drug Administration announced 15 types of missing drugs, including constipation, diarrhea, pain relief, antibiotics, blood pressure, blood lipid reduction drugs, barely can also have alternative drugs to choose, but the first aid intubation drug Cisatracurium is an important life-saving drug for large white lung, can reduce the complications of intubation, "this really can not be ignored!"
Su Yi-feng received a confirmed Taiwanese businessman in January, and the case showed severe pneumonia, commonly known as the "big white lung" symptoms, which at that time was an emergency intubation treatment to save a life.
Su Yi-feng also warned, "I can only ask you to be careful not to be serious about large white lung, the death rate will increase due to lack of medicine."
There were 9,908 new local cases of COVID-19 in China on the 28th, a decrease of 7,069 cases, compared with the 16,911 reported on Tuesday, a decrease of 41.4%. At the same time, 212 new cases of foreign migration and 40 deaths were added.
Luo Yijun, a spokesman for the Central Epidemic Command Center, said that it is expected that the number of confirmed cases will be higher than today's, and will fall between 15,000 and 20,000, and the impact of fake crowds on the rise of the epidemic is expected to be observed on Saturday.
# Drugs # Big White Lung # Su Yifeng # Out of Drugs # Out of Stock

Medication shortages have severe consequences, including the deaths of 146 patients with thalassemia, cystic fibrosis, and hemophilia.

Title:

Content: Human Rights Call to Save Blood Patients and Genetic Diseases in the Gaza Strip
7: 12 pm | 17 April 2024
Palestine today
The Palestinian Center for Human Rights (PCHR) revealed that (18) patients have died of thalassemia since the beginning of the current aggression, while (10) patients are struggling to die after the deterioration of their health condition.
The center said in a statement that most of them resorted to hospitals at the beginning of the aggression to be near the places of medical follow-up, and with the targeting of these hospitals, two of them died, while the rest of the patients face the risk of death due to the severe shortage of medicines and medical supplies, especially (63) patients who remained in Gaza City and North.
He launched an urgent appeal to save the lives of patients in the Gaza Strip, especially blood patients and genetic diseases, whose suffering has been exacerbated by the ongoing Israeli war.
PCHR said that the suffering of Gaza patients has worsened as a result of the severe and dangerous shortage of their medicines, and the consequent serious repercussions that threaten their lives as the war aggression continues for the seventh month in a row.
PCHR issued an urgent appeal for the international community and its humanitarian organizations to assume full responsibility after a number of deaths of patients who have not received their medicines for several months due to the tightening of the Israeli blockade on the Gaza Strip, especially Gaza City and its north, and as a result of the lack of free access for shipments of medicines in sufficient quantities.
He stressed that there are real indications that the occupation forces insist on forcing hundreds of patients to flee from the north of the Gaza Strip to the south, at a time when they dealt a severe blow and destroyed the two most important medical complexes in the Gaza Strip, Al-Shifa Medical Hospital and Nasser Medical Hospital.
She stressed that this means eliminating the hopes of patients to receive appropriate medical services in all areas of the Gaza Strip, and consecrating the crime of genocide, which includes deliberately subjecting the population of the Gaza Strip, including the sick, to living conditions intended to destroy moral and material in whole or in part, in accordance with Article 2 of the 1948 Genocide Convention.
According to the center, (305) patients with thalassemia, including (80) children, suffer from the loss of important drugs such as “EXJADE ” and“ DESFERAL ”, which are prescribed for them for life, and their lack poses a threat to their lives.
The doctors stressed that the symptoms and complications of patients stopping taking these drugs slow their return to the stable state of health in the near term, and constitute a real danger to their lives, especially if the accumulation of iron in their bodies, where accumulation in the pancreas leads to type 1 diabetes, and accumulation in the liver causes fibrosis, and deposition in the heart is one of the leading causes of death for thalassemia patients.
Hussein Naim Karizm, a 31-year-old resident of the northern Gaza Strip town of Jabaliya, said he was unable to move due to severe complications after a long absence from taking iron-repellent drugs, which are not available in the northern Gaza Strip due to the Israeli blockade, in addition to his suffering in providing blood units with the collapse of work in hospital laboratories in the northern Gaza Strip.
“At the beginning of the aggression, we were unable to reach the specialized service center at the Turkish Friendship Hospital because of the difficulty of providing transportation at the time, so I went with a number of my colleagues to Al-Shifa Hospital to obtain blood units, which were provided to us with great difficulty due to the great pressure resulting from the increasing number of wounded. ”
"We receive these units without being tested for viruses and without using blood filters, which puts us at risk for other diseases.
According to the Human Rights Center, about 105 patients suffer from a rare genetic disorder of hemophilia, which is caused by the lack or absence of one of the factors of coagulation in the blood (proteins), often occurs in males; where the patient bleeds after the injury for a longer period than the normal person, and the patient needs lifelong drugs, the most important of which is “FACTOR8 – 9.
Since the first days of the aggression, hemophilia patients have faced many challenges, including the lack of these drugs, which leads to damage to the organs and tissues of patients, as well as poor medical follow-up after the travel of (2) out of (5) doctors who follow genetic blood diseases.
These patients are considered the most affected in case of injury as the war aggression continues, they are at risk of death as a result of difficulty in obtaining their medicines, including analgesics.
The continuation of the war aggression has caused the death of (23) patients out of (360) patients cystic fibrosis, a genetic disorder that causes severe damage to the lungs, digestive system and other organs in the body, and patients need to live with many drugs and chronic treatments such as creon, Gentoycin, and varieties of therapeutic milk in addition to vitamins of all kinds.
The Center said that the depletion of these medicines posed a great danger to their lives, pointing out that a number of these patients in the case of severe danger were evacuated from Gaza City and North for follow-up in the hospitals in the southern Gaza Strip, which did not provide any medical service to them due to the catastrophic conditions.
Among these cases was Malak Jamal Hassan, 22 years old, whose condition worsened due to the lack of medicines and the difficult conditions imposed by the aggression on patients in the Gaza Strip, which necessitated her transfer to the Republic of Egypt for appropriate treatment, while her sister, who was sick with cystic telephones, Alaa Jamal Hassan, 24 years old.
According to their father Jamal Saadat Hassan, 52, his daughters were living with their illness by adhering to the appropriate treatment pattern, despite the difficulty of providing some medicines before the current war aggression, but after they stopped their medication, their condition worsened over the past months.
PCHR called on the international community to force Israel to stop the military aggression and siege on the Gaza Strip, stressing the importance of all patients obtaining their rights to receive appropriate treatment.
He also called on the concerned authorities to provide the necessary capabilities for the work of blood laboratories, especially blood filters and filters to ensure the safety of blood transfusions for these patients.

Iron accumulation in thalassemia patients causes serious complications, which are worsened by medication shortages.

In Lebanon, medicine shortages worsen due to the economic crisis, with cancer treatment drugs running out, potentially shortening patients' lives by 1-3 years.

In Lebanon, medicine shortages worsen due to the economic crisis, with cancer treatment drugs running out, potentially shortening patients' lives by 1-3 years.

In Lebanon, medicine shortages worsen due to the economic crisis, with cancer treatment drugs running out, potentially shortening patients' lives by 1-3 years.